Biotechnology Law Report

Papers
(The TQCC of Biotechnology Law Report is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 137114
The Localization of Drug Patent Linkage System in China: Where Should It Go?4
To What Extent Does Mayo v. Prometheus Allow for the Patenting of Diagnostic Methods?3
Trade Secret Protection on a Publicly Sold, Patented Spinal Implant Device: Life Spine, Inc. v. Aegis Spine, Inc.3
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines3
Legal Governance of Human Gene Editing Technology: From Single Governance to Multiple Governance3
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies2
Selected Developments in Biotechnology Law and the Biotechnology Industry2
Supplementary Protection Certificates in Europe: Clarity at Last?2
Salix Pharms., Ltd. v. Norwich Pharms. Inc.1
Recent Developments in FDA Regulatory Exclusivities1
Univ. of Massachusetts v. L'Oreal S.A.1
Biotechnology and Intellectual Property Law: Theoretical and Practical Reflections on Albanian National Law and Jurisprudence in Comparison with EU Acquis and ECJ Case Law1
Legal and Ethical Challenges in the Construction of China's Biobanks1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp. United States Court of Appeals of the Federal Circuit, 2022 50 F.4th 1471
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
In re Huping Hu: Quantum Entanglement, Medical Innovation, and Patentability on the Scientific “Fringe”1
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
ChromaDex, Inc. v. Elysium Health, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 12801
The Redemption of Drug Patent Linkage System: The Dilemma and Improvement in the Qualification System of Market Exclusivity Period for China’s First Generic Drug1
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws1
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC1
Bio-Rad Lab'ys, Inc. v. Int'l Trade Comm'n1
A Review of Patent Regimes on Health Biotechnology Innovation in India1
A 12th Year 101 Update—Diagnostic and DNA Claims Are Patent Eligible, but Pre-Mayo Patents May Continue to Fall1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Dilemma and Solution of Intellectual Property Protection of Biological Genetic Resources1
Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc.1
United Therapeutics Corp. v. Liquidia Techs., Inc.1
Astellas Pharma, Inc. v. Sandoz Inc. USA, Inc.1
AstraZeneca AB v. Mylan Pharms. Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
In re Entresto1
Pac. Biosciences of California, Inc. v. Pers. Genomics Taiwan, Inc1
ModernaTx, Inc. v. Arbutus Biopharma Corp.1
Research on the Latest Progress of “Mechanism for Early Resolution of Patent Disputes” for Biological Products in China1
China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-191
Moo-re Gene-edited Animals Get Regulatory Clearance: U.S. FDA Approves Genetically Engineered Cattle for Human Consumption1
Hologic, Inc. v. Minerva Surgical, Inc.1
Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.1
Sanho Corp. v. Kaijet Tech. Int’l Ltd., Inc1
An Innovation Principle in Gene Technology Law?1
Landscape of Genome Editing Technology Patents in the European Patent Office with a Focus on CRISPR-Related Opposition Proceedings1
The Evolving Grace Period for U.S. Patent Applicants1
Natera, Inc. v. NeoGenomics Lab’ys, Inc1
Univ. of S. Fla. Bd. of Trustees v. United States1
0.068772077560425